Matthew Baggott to Hallucinogens
This is a "connection" page, showing publications Matthew Baggott has written about Hallucinogens.
Connection Strength
2.980
-
Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers. J Psychoactive Drugs. 2019 Apr-Jun; 51(2):108-117.
Score: 0.529
-
Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J Psychopharmacol. 2016 Apr; 30(4):378-87.
Score: 0.425
-
Intimate insight: MDMA changes how people talk about significant others. J Psychopharmacol. 2015 Jun; 29(6):669-77.
Score: 0.402
-
Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010 Dec 02; 5(12):e14074.
Score: 0.296
-
Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend. 2011 Mar 01; 114(1):61-7.
Score: 0.294
-
Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend. 2010 Oct 01; 111(3):250-6.
Score: 0.293
-
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open. 2024 06 03; 7(6):e2414650.
Score: 0.189
-
Caveat emptor: editors beware. Neuropsychopharmacology. 2001 Apr; 24(4):461-3.
Score: 0.152
-
More about parkinsonism after taking ecstasy. N Engl J Med. 1999 Oct 28; 341(18):1400-1.
Score: 0.137
-
The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? J Psychopharmacol. 2016 12; 30(12):1248-1258.
Score: 0.110
-
Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacology (Berl). 2011 Apr; 214(4):933-9.
Score: 0.074
-
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl). 2002 Aug; 162(4):396-405.
Score: 0.041
-
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000 Dec 19; 133(12):969-73.
Score: 0.037